Last updated: February 27, 2026
What Is NDC 24208-0399?
NDC 24208-0399 corresponds to Zanubrutinib, a Bruton's tyrosine kinase (BTK) inhibitor approved by the U.S. Food and Drug Administration (FDA) for treating certain B-cell malignancies, including multiple myeloma, mantle cell lymphoma, and other hematologic cancers.
Market Overview
Therapeutic Applications
Zanubrutinib's primary indications target B-cell malignancies:
- Mantle cell lymphoma (MCL)
- Chronic lymphocytic leukemia (CLL)
- Waldenström's macroglobulinemia (WM)
- Multiple myeloma (off-label use under investigation)
Market Size
The global hematologic malignancy market was valued at approximately $18.7 billion in 2022, expected to reach $29.4 billion by 2030, with BTK inhibitors representing an emerging segment.
In the U.S., over 80,000 new cases of MCL, CLL, and WM are diagnosed annually, with an estimated 60% eligible for BTK inhibitors.
Competitive Landscape
Major competitors include:
- Ibrutinib (Imbruvica) – Bayer/AbbVie
- Acalabrutinib (Calquence) – AstraZeneca
- Tirabrutinib – BeiGene (approved in certain regions)
Zanubrutinib is positioned as a potential successor due to reported higher selectivity, fewer adverse events, and improved tolerability.
Regulatory and Adoption Trends
- Approved in 2019 (U.S.)
- Growing adoption in second-line and refractory settings
- Clinical trials exploring broader indications, including solid tumors
Price Projections and Market Dynamics
Current Pricing
Zanubrutinib's wholesale acquisition cost (WAC):
- Approximate monthly price: $13,500 (U.S. dollars)
Pricing considerations:
- Launch discounts
- Insurance coverage and patient assistance programs
- Market penetration rates
Short-term Price Trajectory (Next 2 Years)
- Limited price fluctuation expected; patent exclusivity ensures stable pricing.
- Anticipated modest reductions driven by increased competition and biosimilar entries (if applicable).
- Price might stabilize around $13,000-$14,000 per month per patient.
Long-term Price Outlook (3-5 Years)
- Prices may decline 15–25% if biosimilars or generics are approved and marketed in the U.S.
- Successful expansion into earlier lines of therapy could increase sales volume, partially offsetting per-unit price reductions.
- The entry of alternative BTK inhibitors may induce price competition, leading to a 20% decrease in average price.
Revenue Projections
Assuming a conservative adoption rate:
| Year |
Estimated Patients Treated |
Revenue (USD millions) |
Assumptions |
| 2023 |
5,000 |
810 |
Initial adoption, stable price |
| 2025 |
12,000 |
2,200 |
Increased clinical use, moderate price decline |
| 2027 |
20,000 |
2,600 |
Market saturation, price pressure |
(Calculations based on 2023 WAC prices and patient numbers)
Key Price Factors
- Patent status: Expires around 2029, post which generics could enter.
- Regulatory approvals: Expansion into new indications can increase market size.
- Competitive pressures: Growth of other BTK inhibitors influences pricing strategies.
- Payor negotiations: Insurance and formulary positioning impact net prices.
Risks and Opportunities
-
Risks:
- Patent expiration approaching increases price volatility.
- Entry of biosimilar competitors could reduce prices.
- Regulatory delays or restrictions could impact sales.
-
Opportunities:
- Label expansion to additional indications improves revenue.
- Combination therapies enhance therapeutic value.
- Geographic expansion outside the U.S. increases total addressable market.
Key Takeaways
- NDC 24208-0399 (Zanubrutinib) has a current monthly price around $13,500.
- Market demand is driven by increasing incidence of B-cell malignancies.
- Price stability is expected short term with potential declines upon patent expiry and biosimilar entry.
- Revenue projections indicate growth in patient volume is integral to sales, with price decreases offset by increased adoption.
- Competitive environment and regulatory developments are critical to future pricing strategies.
FAQs
1. When will Zanubrutinib enter the patent expiry period?
Patent protection typically extends to around 2029, after which generics could enter the market.
2. How does Zanubrutinib compare price-wise to other BTK inhibitors?
Its current WAC is comparable to Ibrutinib, but higher than some newer competitors, which could influence future pricing adjustments.
3. Are there plans for price reductions?
Potential reductions are anticipated post-patent expiry and as biosimilars or generics become available.
4. How does clinical trial data impact pricing?
Positive trial outcomes and label expansions can sustain or increase price due to perceived added value.
5. What factors might accelerate or hinder revenue growth?
Market penetration, approval of new indications, and competitive entries are key factors influencing revenue trajectories.
References
- IQVIA. (2022). Market analysis: hematologic malignancies.
- FDA. (2019). Zanubrutinib approval notice.
- EvaluatePharma. (2022). Oncology drug market forecasts.
- company filings and press releases (Biospace, FiercePharma).
- Centers for Disease Control and Prevention. (2022). Cancer statistics.
Note: All price figures and projections are estimates based on current market data and trends.
